Straits Times Index
3,264.53 -35.51 (-1.08%) S&P 500
5,189.64 +1.94 (+0.04%) Dow
39,061.33 +177.07 (+0.46%) Nasdaq
16,308.17 -24.38 (-0.15%) Bitcoin USD
62,101.77 -1,014.87 (-1.61%) CMC Crypto 200
1,323.57 +28.90 (+2.23%)
Erasca, Inc. (ERAS)
| Previous close | 2.1800 |
| Open | 2.1800 |
| Bid | 2.1200 x 100 |
| Ask | 2.1900 x 100 |
| Day's range | 2.1000 - 2.1800 |
| 52-week range | 1.5100 - 3.3750 |
| Volume | |
| Avg. volume | 801,152 |
| Market cap | 370.121M |
| Beta (5Y monthly) | 1.10 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Erasca to Present at the Bank of America Health Care Conference
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank of America Health Care Conference being held at the Encore Hotel in Las Vegas, Nevada. Management will present on Wednesday, May 15, 2024 at 4:20 pm Pacific Time and will also participate in one-on-one investo
- GlobeNewswire
Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting
Oral presentation will feature updated HERKULES-3 results for ERK1/2 inhibitor ERAS-007 in combination with encorafenib and cetuximab in BRAFm colorectal cancer Poster presentations will feature SEACRAFT-1 Phase 1 trial design for naporafenib plus trametinib in RAS Q61X mutations, and preliminary FLAGSHP-1 Phase 1 results for ERAS-601 and cetuximab in chordoma SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused
- GlobeNewswire
Erasca Announces $45 Million Oversubscribed Private Placement Financing
Funding from new and existing investors extends anticipated cash runway into H2 2026SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS) (“Erasca”), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell 21,844,660 shares o
